Hesperidin: meta-analysis of COVID-19 studies

All studies   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
Meta-analysis1 study · 211 patientsc19early.org

Hesperidin for COVID-19

Serious outcome risk
Hesperidin
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−209%
RCTs (1)−209%
Early (1)−209%
00.511.5+
← Hesperidin
reduces riskIncreased
risk →
c19early.org
October 2026

Hesperidin COVID-19 studies (+1 unreported RCT)

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dupuis (DB RCT)−209%3.09 · 0.33–29.20progression3/1041/107 Okasha (DB RCT)n/a< NOT REPORTED >100 (est. total)>5 years late
Early treatment−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.33
All studies−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3300.511.52+
Rotate screen for more detailsIncrease width for more details
← Hesperidin
reduces riskHesperidin
increases risk →
c19early.org
October 2026

Hesperidin COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dupuis (DB RCT)−209%3.09 · 0.33–29.20progression3/1041/107
Early treatment−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.33
All studies−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3300.511.52+
Rotate screen for more detailsIncrease width for more details
← Hesperidin
reduces riskHesperidin
increases risk →
c19early.org
October 2026

Hesperidin COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dupuis (DB RCT)31%0.69 · 0.38–1.27no recov.104 (n)107 (n)
Early treatment31%0.69 · 0.38–1.27104 (n)107 (n)31% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.23
All studies31%0.69 · 0.38–1.27104 (n)107 (n)31% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.2300.511.52+
Rotate screen for more detailsIncrease width for more details
← Hesperidin
reduces riskHesperidin
increases risk →
c19early.org
October 2026

Hesperidin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dupuis (DB RCT)−209%3.09 · 0.33–29.20progression3/1041/107 Okasha (DB RCT)n/a< NOT REPORTED >100 (est. total)>5 years late
Early treatment−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.33
All studies−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3300.511.52+
Rotate screen for more detailsIncrease width for more details
← Hesperidin
reduces riskHesperidin
increases risk →
c19early.org
October 2026

Hesperidin COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dupuis (DB RCT)−209%3.09 · 0.33–29.20progression3/1041/107
Early treatment−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.33
All studies−209%3.09 · 0.33–29.203/1041/107209% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3300.511.52+
Rotate screen for more detailsIncrease width for more details
← Hesperidin
reduces riskHesperidin
increases risk →